Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evexomostat (SDX-7320) in advanced solid tumors
NCT02743637Phase 1Completed
- Sponsor
- SynDevRx, Inc.
- Start
- Feb 2016
- Primary completion
- Dec 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evexomostat in solid tumor (advanced stage), sponsored by SynDevRx, Inc. Primary endpoint: Number of participants with adverse events. Started Feb 2016; status: completed.
02
Drugs
evexomostat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02743637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743637.